

<u>Short Name</u>	<u>Comments</u>	<u>Type</u>	<u>Investigator</u>	<u>Contact</u>
Wii Study	Managing Fatigue Using Virtual Reality for Post-Operative Lung Cancer Patients: Understanding the Post-Surgical Non-Small Cell Lung Cancer (NSCLC) Patient's Symptom Experience	Treatment	SHORE: Drs. Geoffrey Lam and Charles Wilekes	Cardiovascular Research Department (616) 391-3886
2019-278 SEER-Lung	A Prospective Blood Sample Collection Study to Develop and Validate a Panel of Protein-based Biomarkers in Patients with Pulmonary Nodules	Other	SHORE: Dr. Glenn VanOtteren	Tara Jager (616) 391-5038 tara.jager@spectrumhealth.org
A151216	Non-Squamous, Large IB, II or IIIA, any EGFR/ALK, Resected. Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (<u>ALCHEMIST</u>)	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
E4512	Must be enrolled in A151216. NSCLC; ALK+; Surgically Resected Early Stage. <u>Crizotinib/Placebo</u>	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
A081105	Must be enrolled in A151216. NSCLC; EGFR Mutant, Resected Tumor. Treatment <u>Erlotinib/Placebo</u>	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
A221504	A Randomized, Double-blind, Placebo-controlled Pilot Study of an Oral, Selective Peripheral Opioid Receptor Antagonist in Advanced Non-small Cell Lung Cancer (Adenocarcinoma)	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
NRG LU005	Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase II/III Randomized Study of Chemoradiation vs Chemoradiation + Atezolizumab	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org

S1827	S1827 - MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
S1900B	S1900B - A Phase II Study of LOXO-292 in Patients with RET Fusion-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
EA5163: INSIGNA	A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-Driven Analysis	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
S1800A	A Phase II RANDOMIZED Study of Ramucirumab Plus MK3475 (Pembrolizumab) versus Standard of Care for Patients Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
S1900A	A Phase II Study of Rucaparib in Patients with Genomic LOH High And/Or Deleterious Brca1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-Map Sub-Study)	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org

SWOG LungMAP	A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)	Screening	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
EA5162	Phase II study of AZD9291 (Osimertinib) advanced NSCLC Patients with Exon 20 Insertion	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
NRG LU002	A Randomized Phase II/III Trial for Maintenance Systemic Therapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Systemic therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC)	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
NRG CC003	Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
S1900C	A Phase II Study of Talazoparib Plus Avelumab in Patients with Stage IV or Recurrent Non-Squamous Cell Lung Cancer Bearing Pathogenic STK11 Genomic Alterations (Lung-MAP Sub Study)	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
S1929	Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination with Talazoparib in Patients with SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org

CARMEN	Randomized, Open Label Phase 3 Study of SAR408701 versus Docetaxel in Previously Treated metastatic non-squamous non-small Cell Lung Cancer patients with CEACAM5 positive tumors	Treatment	CHCWM Physician Investigators	CHCWM (616) 954-9800 www.chcwm.com
GX41563	A Multi-center, Low-intervention Study to Evaluate the Feasibility of a Prospective Clinicogenomic Program	Other	CHCWM Physician Investigators	CHCWM (616) 954-9800 www.chcwm.com
ADRIATIC	AstraZeneca (ADRIATIC): A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with State I-III Limited Disease Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy	Treatment	CHCWM Physician Investigators	CHCWM (616) 954-9800 www.chcwm.com
IPSEN MM-398-01-03-04	RESILIENT: A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection (ONIVYDE) versus Topotecan in Patients with Small Cell Lung Cancer or after Platinum-based First-line Therapy	Treatment	CHCWM Physician Investigators	CHCWM (616) 954-9800 www.chcwm.com
Helsinn (ANAM)	A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)	Treatment	CHCWM Physician Investigators	CHCWM (616) 954-9800 www.chcwm.com

CodeBreak200: 20190009	A Phase III Multicenter, Randomized, Open-label, Active-controlled, Study of AMG 510 vs Docetaxel for the Treatment of Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC Subjects with Mutated KRAS p.G12C	Treatment	CHCWM Physician Investigators	CHCWM (616) 954-9800 www.chcwm.com
Amgen 20190294	A Biomarker Study on Tumor Tissue in Subjects with Non-small Cell Lung Cancer	Diagnostic	CHCWM Physician Investigators	CHCWM (616) 954-9800 www.chcwm.com
	An Open Label, Single Arm, Phase IB/II Study to Evaluate the Safety and Efficacy of Grapiprant (ARY-007) in Combination with Pembrolizumab in Patients with Advanced or Metastatic Post-PD-1/L1 Non-small Cell Lung Cancer (NSCLC) Adenocarcinoma	Treatment	START Midwest Investigators	START Midwest (616) 954-5554